NCT05242744 FTT PET/CT in Metastatic Prostate Cancer
| NCT ID | NCT05242744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Prostate Cancer Metastatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-03-01 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Eligibility Criteria
Inclusion Criteria: 1. Participants will be ≥ 18 years of age 2. Histologically proven prostate carcinoma 3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound) 4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care. 5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 2. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Contact & Investigator
Neil Taunk, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT05242744 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05242744 currently recruiting?
Yes, NCT05242744 is actively recruiting participants. Contact the research team at erin.schubert@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05242744 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05242744 clinical trial?
NCT05242744 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Neil Taunk, MD at University of Pennsylvania. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.